Mineral and Bone Disorder: Resources for Healthcare Professionals

This bulletin focuses on vitamin D physiology and nomenclature, vitamin D metabolism and catabolism in CKD, as well as, the central role that vitamin D plays in secondary hyperparathyroidism. As part 1 of a 2-part series, it provides insight into the importance of monitoring patients with CKD for secondary hyperparathyroidism and the need to treat vitamin D deficiency.

This educational resource is designed to increase professional awareness and knowledge about vitamin D deficiency and secondary hyperparathyroidism in CKD stages 3-4. It covers indications of vitamin D supplementation in patients with CKD, as well as the importance of vitamin D testing and the need for the standardization of 25(OH)D measurement. There is also a review of conventional and novel therapeutic options for vitamin D supplementation for the prevention and treatment of secondary hyperparathyroidism in patients with CKD.

This is a laminated reusable card for clinicians to use when teaching patients with CKD stage 3-4 about secondary hyperparathyroidism, Vitamin D deficiency, and CKD Mineral and Bone Disorder (CKD-MBD).

This is a take home sheet for clinicians to give to patients when teaching them about CKD stage 3-4 about secondary hyperparathyroidism, Vitamin D deficiency, and CKD Mineral and Bone Disorder (CKD-MBD). To be used in conjunction with the Clinician Teaching Card.

This resource page includes a list of relevant literature related to vitamin D deficiency.

This fact sheet is designed to raise awareness about the link between reduced glomerular filtration rate (GFR) and vitamin D deficiency. It also contains interesting facts and statistics about CKD-MBD.

This poster includes information about secondary hyperparathyroidism, vitamin D deficiency, and CKD-mineral bone disorder (CKD-MBD). It is for patients with CKD stages 3-4.

The clinical bulletin provides insight into the complex relationship interrelationship between phosphorus, calcium and intact parathyroid hormone and highlights the use of composite risk categories to help practitioners determine priorities in treating CKD-MBD.